News

In May 2008, Pharmacopeia reduced its workforce by approximately 15% through attrition and termination of positions. With these two reductions, the company will have reduced its workforce in

The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A. The initiation of the Phase I clinical trial resulted in the

AGS-004 achieved the trial’s primary endpoint of induction of T cell response to patient-specific HIV antigens. AGS-004 is a personalized HIV immunotherapy generated by the company’s Arcelis technology.

Vyteris’s pain management initiative will examine several candidate drugs to improve their safety and efficacy profiles using the company’s proprietary controlled drug delivery technology and to potentially extend

The Office of the Chief Scientist (OCS) has approved a special grant to support Modigene’s interferon-beta-CTP (IFN-Beta-CTP) program for 2008-2009. The grant will provide cash reimbursements of 40%

The patent-pending modular forceps and accessories are said to be designed to provide surgeons added comfort while reducing per-procedure costs through the reduction of inventory and obsolescence. According

TriMix gel has been prescribed by doctors as a first line and secondary treatment for erectile dysfunction (ED). American Pharmacy Solutions (APS) is a licensed compounding pharmacy which

The test provides oncologists with a new tool for monitoring blood level of 5-FU in cancer patients undergoing chemotherapy. This rapid test is said to be faster than

In order to preserve the company’s remaining cash resources, the company’s employees were released from employment, except for Shawn Cain, the company’s president and CEO, and Scott Hayashi,